Ashley Zehnder, the founder and CEO of Fauna Bio, dives into the fascinating world of hibernation and its secrets for human health. She discusses how the genomic data from hibernating animals can unlock potential treatments for obesity, heart attacks, and more. With her company's use of AI, they're identifying gene-disease links that could lead to groundbreaking drug therapies. The partnership with Eli Lilly highlights the innovative strategies being used in drug discovery, particularly in tackling obesity and enhancing our understanding of tissue regeneration.
Understanding the biology of hibernation can lead to new drug innovations for obesity, heart disease, and neuroprotection.
Fauna Bio's AI platform utilizes genomic data from hibernating animals to enhance drug discovery and develop innovative therapeutic targets.
Deep dives
Exploration of Hibernation's Biology
Hibernation demonstrates remarkable biological adaptations that go beyond simple dormancy, with animals able to undergo severe physiological changes without suffering tissue damage. Research into this phenomenon spans decades and reveals similar hibernation traits in a range of mammals, underscoring the evolutionary advantages conferred by these adaptations. Notably, hibernating animals show profound abilities to repair heart damage and maintain muscle integrity during extended periods without food or water. FaunaBio focuses on leveraging genomic data from these animals to uncover insights that could inform treatments for human health conditions such as obesity, heart disease, and neurodegenerative disorders.
FaunaBio's Unique Approach to Drug Discovery
FaunaBio applies an innovative AI-driven approach to drug discovery that bridges human health and animal genomics, aiming to identify new therapeutic targets based on the genetic analysis of hibernating species. By studying how these animals manage critical physiological challenges, such as hypoxia and reperfusion injuries, the company seeks to replicate these protective mechanisms in human applications. Their platform enables them to map small molecule compounds to relevant genes, facilitating quicker innovations in drug development. This strategy not only enhances the efficiency of the discovery process but also reduces costs significantly compared to traditional methods.
Current Research and Collaborations
FaunaBio collaborates with major organizations, including Eli Lilly, to explore novel obesity treatments inspired by hibernation biology. The partnership focuses on identifying unique gene targets that facilitate metabolic flexibility and sustainable weight loss, moving beyond current drugs that require continuous administration. Additionally, FaunaBio engages in projects with NASA to study hibernation's potential to protect astronauts from the physiological challenges associated with long-term space travel. These collaborations highlight the practical applications of their research in addressing critical health issues both on Earth and beyond.
Funding and Future Prospects
FaunaBio's funding strategy combines venture capital investments and government grants, providing a solid financial foundation to advance their research initiatives. With backing from notable investors and strategic partnerships, the company aims to develop its own therapeutic pipeline while concurrently fostering collaborative efforts with pharmaceutical giants. Their existing funding supports ongoing projects, but plans for a future Series A funding round will aim to propel their lead programs into clinical development. As FaunaBio continues to explore the intersection of animal genomics and human health, its innovative technology positions it for significant advancements in drug discovery.
Hibernation is not just a matter of deep sleep. Animals that hibernate are able to do so without suffering damage to tissue and muscle. Understanding the biology of hibernation can unlock potential insights into obesity, heart attack and stroke, muscle atrophy, neuroprotection, and longevity. Fauna Bio is studying genomic data from so-called "extreme mammals" and applying its proprietary AI platform to perform comparative genetic analysis to find gene-disease links and leverage millions of years of evolutionary adaptations to identify new therapeutic opportunities for human health. We spoke to Ashley Zehnder, founder and CEO of Fauna Bio, about the types of insights that can be gleaned from the genetics of hibernating animals, the wide range of human health conditions that might be addressed with such an approach, and the company’s deal with Eli Lilly to apply its AI platform to discover new obesity drugs.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode